Leerink Partnrs Issues Optimistic Estimate for KYMR Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Kymera Therapeutics in a research note issued on Thursday, October 31st. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings of ($3.04) per share for the year, up from their previous forecast of ($3.25). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.85) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics' Q4 2024 earnings at ($0.94) EPS, Q1 2025 earnings at ($0.99) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($4.18) EPS and FY2026 earnings at ($4.13) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 28.05%. The business had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. During the same period in the previous year, the business posted ($0.90) earnings per share. Kymera Therapeutics's revenue for the quarter was down 20.9% on a year-over-year basis.

A number of other equities research analysts have also weighed in on KYMR. Leerink Partners restated an "outperform" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Monday, September 9th. Guggenheim boosted their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a report on Friday. Wells Fargo & Company boosted their price objective on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an "equal weight" rating in a report on Monday, August 12th. B. Riley boosted their price objective on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a "neutral" rating in a report on Tuesday, July 9th. Finally, UBS Group lowered their price objective on shares of Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating for the company in a report on Monday. Four research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $50.93.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock traded up $0.60 during mid-day trading on Monday, hitting $47.07. 303,479 shares of the company traded hands, compared to its average volume of 596,018. Kymera Therapeutics has a one year low of $13.85 and a one year high of $53.27. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of -20.04 and a beta of 2.21. The stock has a fifty day moving average price of $47.04 and a 200-day moving average price of $40.75.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Kymera Therapeutics by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company's stock valued at $101,778,000 after acquiring an additional 72,351 shares during the period. Principal Financial Group Inc. lifted its stake in Kymera Therapeutics by 4.7% during the 1st quarter. Principal Financial Group Inc. now owns 12,098 shares of the company's stock valued at $486,000 after acquiring an additional 547 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Kymera Therapeutics by 6.7% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,471 shares of the company's stock valued at $984,000 after acquiring an additional 1,531 shares during the period. FORA Capital LLC bought a new position in Kymera Therapeutics during the 1st quarter valued at about $818,000. Finally, Jennison Associates LLC bought a new position in Kymera Therapeutics during the 1st quarter valued at about $17,122,000.

Insider Buying and Selling at Kymera Therapeutics

In other news, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, Director Jeffrey W. Albers sold 5,000 shares of the company's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. Insiders own 15.82% of the company's stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.